fasudil has been researched along with antipyrine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, T; Ikegaki, I; Iwasaki, M; Satoh, S; Toshima, Y | 1 |
| Asano, T; Hitomi, A; Ikegaki, I; Satoh, S; Seto, M; Toshima, Y | 1 |
2 other study(ies) available for fasudil and antipyrine
| Article | Year |
|---|---|
Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Cell Death; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavengers; Gerbillinae; Ischemia; Male; Neurons; Neuroprotective Agents; Time Factors | 2007 |
Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Blood Flow Velocity; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Intracranial Thrombosis; Lauric Acids; Male; Myosins; Protein Binding; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Regional Blood Flow; rho-Associated Kinases; Time Factors | 2008 |